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Abstract
Overexpression of ecotropic viral integration site 1 (EVI1) is associated with aggressive disease in acute myeloid leukemia
(AML). Despite of its clinical importance, little is known about the mechanism through which EVI1 confers resistance to
antileukemic drugs. Here, we show that a human myeloid cell line constitutively overexpressing EVI1 after infection with
a retroviral vector (U937_EVI1) was partially resistant to etoposide and daunorubicin as compared to empty vector infected
control cells (U937_vec). Similarly, inducible expression of EVI1 in HL-60 cells decreased their sensitivity to daunorubicin.
Gene expression microarray analyses of U937_EVI1 and U937_vec cells cultured in the absence or presence of etoposide
showed that 77 and 419 genes were regulated by EVI1 and etoposide, respectively. Notably, mRNA levels of 26 of these
genes were altered by both stimuli, indicating that EVI1 regulated genes were strongly enriched among etoposide regulated
genes and vice versa. One of the genes that were induced by both EVI1 and etoposide was CDKN1A/p21/WAF, which in
addition to its function as a cell cycle regulator plays an important role in conferring chemotherapy resistance in various
tumor types. Indeed, overexpression of CDKN1A in U937 cells mimicked the phenotype of EVI1 overexpression, similarly
conferring partial resistance to antileukemic drugs.
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Introduction
Aberrant expression of the ecotropic viral integration site 1 (EVI1)
gene, which in healthy individuals is transcribed in hematopoietic
stem and progenitor cells but not in mature blood cells [1,2,3,4], is
associated with a poor prognosis in myeloid leukemias
[2,5,6,7,8,9,10,11,12,13]. EVI1 overexpression also correlates with
shorter survival in some solid tumors like ovarian carcinoma [14]
and estrogen receptor negative breast cancer [15]. Despite the well
documented importance of EVI1 in predicting and most likely
causing chemotherapy resistance in human malignant diseases,
knowledge about its mechanism of action is limited. EVI1 is
thought to act mainly as a transcription factor, and a recent
publication provided a comprehensive overview of genes that are
directly regulated by EVI1 in ovarian carcinoma cells [16].
However, only a small number of EVI1 target genes have been
functionally characterized so far. Among them, the phosphatase and
tensin homolog (PTEN) gene appears to be of particular interest, as
direct repression of PTEN by EVI1 lead to activation of the AKT/
mTOR pathway in murine bone marrow cells, and rapamycin
prolonged survival of mice with EVI1 overexpressing leukemias
[17]. Increased AKT signalling is frequently observed in acute
myeloid leukemia (AML) and has been reported to be associated
with poor outcome [18,19]. However, recent results indicate that
in fact the opposite may be true [20,21,22], so that it is presently
unclear to which extent activation of the AKT pathway can
explain the poor prognosis associated with EVI1 overexpression in
AML.
Nonetheless, enhancement of AKT signalling has also been
implicated in EVI1 mediated resistance to transforming growth
factor beta (TGF-b) and taxol induced apoptosis in colon cancer
cells [23]. EVI1 also increased cellular resistance towards
ultraviolet (UV) light [24], tumor necrosis factor a (TNF-a) [24],
and interferon a (IFN-a) [25]. In addition to activation of the
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AKT pathway [23], inhibition of the proapoptotic jun N-terminal
kinase (JNK) [24] and repression of the induction of the
promyelocytic leukemia (PML) gene [25] have been reported as
possible mechanisms for EVI1 induced apoptosis resistance. Thus,
several studies have addressed the role of EVI1 in protecting cells
from apoptotic stimuli, yet little information is available regarding
a possible effect of EVI1 on cellular resistance to drugs used in the
therapy of AML.
The protein product of the CDKN1A/p21/WAF gene, p21, is
a 165 amino acid protein best known for its role in mediating p53
dependent cell cycle arrest [26]. In agreement with a tumor
suppressive role of this gene, many human cancers exhibit low
levels of p21 protein, and experimental ablation of CDKN1A
promotes tumor formation in mice [26]. On the other hand,
CDKN1A may also be overexpressed in human malignancies, and
this molecular alteration is associated with therapy resistance and
poor survival [26,27,28]. Accordingly, p21 protects cells from
apoptosis induced by DNA damaging agents and other kinds of
stress in vitro and in vivo [26,27,29,30,31,32,33,34,35,36,37]. Pre-
existing p21 may play a role in increased apoptosis resistance in
some cases [27,28,38]. In addition, many of the stimuli from which
it protects themselves induce p21 [26,29,31,32,33,34,37,39]. The
regulation of CDKN1A/p21/WAF is complex and involves
a number of transcription factors in addition to p53, as well as
posttranscriptional mechanisms like mRNA-miRNA interactions
and phosphorylation, which, among others, affects its subcellular
location [26,27,37,39]. The antiapoptotic function of p21 has
often been associated with its residence in the cytoplasm [27,34],
where it inhibits proapoptotic molecules like JNK and caspases
[26]. However, nuclear activities of p21 also contribute to its
survival promoting activity: apart from an indirect effect through
cell cycle inhibition, its ability to directly bind to and inhibit the
activity of transcription factors like E2F1 and MYC plays a role
[26,34].
In AML, overexpression of p21 protein relative to healthy
controls was found in 17/100 patient samples, and was associated
with worse complete response rates and shorter overall survival
[28]. Agents used for chemotherapy in AML like etoposide and
anthracyclines induced CDKN1A/p21/WAF in a variety of cell
types, including hematopoietic cells [29,31,32,33,34,37,39], and
p21 protected hematopoietic cells from apoptosis
[29,30,31,33,35,36]. In addition to cytostatic agents, leukemogenic
oncoproteins like BCR-ABL, PML-RARa, AML1-ETO, and
FLT3-ITD induced p21 in myeloid cells [35,40,41]. Experimental
ablation of p21 in PML-RARa and AML1-ETO expressing
hematopoietic cells increased the number of double strand breaks
induced by these fusion proteins and reduced their leukemogeni-
city, suggesting that protection from excessive oncogene induced
DNA damage by p21 was essential for the maintenance of
leukemia stem cells in this context [40].
In the present report we describe an in vitro model that
recapitulates the resistance of EVI1 overexpressing cells to drugs
used in the chemotherapy of AML, and show that this effect may
in part be mediated by upregulation of CDKN1A/p21/WAF.
Materials and Methods
Ethics Statement
Animal experiments were approved by the ethics committee of
the Medical University of Vienna and the Bundesministerium fu¨r
Wissenschaft und Forschung Ref. II/10b (Gentechnik und
Tierversuche), application Nr. BMWF-66.009/0095-II/10b/
1010, and were carried out according to the Austrian and
FELASA guidelines for animal care and protection in order to
minimize distress for the animals. Mice were sacrificed by cervical
dislocation.
Cell Culture, Retroviral Vectors, and Infections
The human hematopoietic cell lines U937 [42], HNT-34 [43],
and HL-60 [44] were cultured in RPMI 1640 (Life Technologies,
Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Life
Technologies) and 1% Penicillin/Stretopmycin/Glutamine (PSG;
Life Technologies) in a humidified incubator at 37uC and 5%
CO2. Phoenix-gp cells (http://www.stanford.edu/group/nolan/
retroviral_systems/phx.html) were cultured in DMEM (Life
Technologies) with 10% FBS and 1% PSG at 37uC and 5% CO2.
The full length cDNA of the human EVI1 gene, which codes for
a 1051 amino acid protein, was cloned into the BamHI and EcoRI
sites of the retroviral vector pBMN_IRES-eGFP (Addgene,
Cambridge, MA, USA) to yield pBMN_EVI1-IRES-eGFP using
standard molecular biology techniques. For doxycycline inducible
expression of human EVI1, a codon optimized version of its cDNA
(Geneart, Regensburg, Germany) was inserted into the BamH1
and AsiSI sites of pCCL.SIN.cPPT.TRE.IRES.eGFP.wPRE
(F.H., unpublished results) and verified by sequencing. The
human CDKN1A gene was amplified from cDNA from etoposide
treated U937_EVI1 cells using primers CDKN1A_fwd (59-
CACGGATCCGAGGCGCCATGTCAGAAC-39) and
CDKN1A_rev (59-CTGACTCGAGGGAT-
TAGGGCTTCCTCTTGG-39) and Phusion High Fidelity Poly-
merase (New England Biolabs, Ipswich, MA, USA). It was cloned
into the retroviral vector pMIA-II_IRES-Ametrine using the
BamHI and XhoI sites to yield pMIA-II_CDKN1A-IRES-
Ametrine. The identity of the insert was confirmed by DNA
sequence analysis. pMIA-II_IRES-Ametrine was a kind gift from
Dr. Dario Vignali of the St. Jude Children’s Research Hospital,
Memphis, Tennessee. Ametrine is a fluorescence marker with
spectral properties similar to those of Cyan Fluorescent Protein
(CFP), but brighter.
Retroviral particles were generated and U937 and their
derivative cell lines infected using standard procedures [45].
Three days later, cells were sorted for enhanced Green Fluorescent
Protein (eGFP) or Ametrine positivity on a FACS Aria (Becton
Dickinson, Franklin Lakes, NJ, USA). Cell line authentication by
short tandem repeat profiling (performed by Ingenetix, Vienna,
Austria) confirmed the identity of pBMN_EVI1-IRES-eGFP and
Table 1. Primers used for amplification and sequence analysis
of the integrated, vector borne EVI1 gene from U937_EVI1
cells.
Primer name sequence (59–39)
F1-F* GCTTGGATACACGCCGC
F1-R GGTCACTGCCACTTGGTGTA
F2-F GAGGTTTTGTGAGGGCAAGA
F2-R ACCCACTCCTTTCTTTATGGACC
F3-F ACCCACACAGGAGAGCAGCC
F3-R TACGTGGCTTATGGACTGGATAGCAC
F4-F AGCAACGTCGAATCAAGACCTGCTTCAGAT
F4-R CGGACTAGTTGCTGTACCGGACATGTTCCC
F5-F TGCTCTAGATCATATAAGGCA
F5-R* GGAGAGGGGCGGAATTTAC
*Primers F1-F and F5-R match the vector, rather than the EVI1, sequence.
doi:10.1371/journal.pone.0056308.t001
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pBMN_IRES-eGFP infected cells (U937_EVI1 and U937_vec
cells, respectively) as U937 derivatives. To generate HL-60 cells
expressing EVI1 in a doxycycline inducible manner, parental HL-
60 cells were first infected with pLVX-Tet-On Advanced
(Clontech, Mountain View, CA, USA) using previously described
methodology [46]. After selection with 1 mg/ml G418 (Clontech),
rtTA expressing cells were transduced with pCCL.SIN.cPPT.-
TRE.EVI.IRES.eGFP.wPRE or empty vector as a control,
yielding HL-60_EVI1 and HL-60_vec cells, respectively. Trans-
duced cultures were induced for 48 h with 2 mg/ml doxycycline
(Clontech) and sorted for eGFP positivity. Doxycycline inducible
gene expression was verified by FACS and immunoblot analysis.
Sequence Analysis
The CDKN1A cDNA in pMIA-II_IRES-Ametrine was se-
quenced using the primers used for PCR amplification. Sequence
analysis of the integrated exogenous EVI1 gene in U937_EVI1
cells was performed after amplification of 5 overlapping gene
segments covering the entire EVI1 coding sequence from genomic
DNA isolated from U937_EVI1 cells after several weeks in
culture. Primers used for amplification of EVI1 are shown in
Table 1. Capillary sequencing was performed by Eurofins-MWG-
Operon (Ebersberg, Germany).
Integration Site Analysis by LAM-PCR
500 ng genomic DNA, isolated from U937_vec and
U937_EVI1 cells either shortly after infection and sorting or after
12–15 weeks in culture, were digested with Tsp509I or HinPI and
used for the analysis of integration sites by 59-LTR-mediated
linear amplification mediated (LAM)-PCR as previously described
[47]. Briefly, linear PCR was performed using vector specific 59-
biotinylated primers LTRa bio (59-TGCTTACCACAGA-
TATCCTG-39) and LTRb bio (59-ATCCTGTTTGGCCCA-
TATTC-39). For the first and second exponential PCRs, vector
specific primers LTR II bio (59- GACCTTGATCT-
GAACTTCTC-39) and LTR III bio (59-TTCCATGCCTTG-
CAAAATGGC-39) were used in combination with linker cassette
specific primers LC I (59-GACCCGGGAGATCTGAATTC-39)
and LC II (59-GATCTGAATTCAGTGGCACAG-39). 5% of the
LAM-PCR amplicons were separated on a Spreadex high-
resolution gel (Elchrom Scientific, Cham, Switzerland).
For high throughput pyrosequencing (GS FLX, Roche Diag-
nostics, Risch, Switzerland), 40 ng per sample were prepared
according to the manufacturer’s protocol. Approximately 26.000
sequence tags were obtained from each sample. They were
mapped to the human genome using the UCSC blast-like
alignment tool (BLAT) (GRCh37/hg19, Feb 2009, available at
http://www.genome.ucsc.edu/cgi-bin/hgBlat).
Microarray Analyses
RNA for microarray analyses was extracted from two in-
dependent replicate cultures of U937_vec and U937_EVI1 cells
treated or not treated with 400 nM etoposide for 48 h using the
RNeasy Plus Mini kit (Qiagen, Hilden, Germany). RNA quality
control, labelling, hybridization to Human Gene 1.1 ST arrays
(Affymetrix, Santa Clara, CA, USA), and primary data analysis
using the Affymetrix RMA algorithm were performed at the
Center of Excellence for Fluorescent Bioanalytics (KFB; Regens-
burg, Germany). Genes whose expression changed at least twofold
in response to EVI1 (in the absence of etoposide) or to etoposide (in
the absence of EVI1) in both replicate experiments were
considered as regulated by the respective stimulus.
RNA Extraction, Reverse Transcription, and Real Time
Quantitative Reverse Transcriptase Polymerase Chain
Reaction (qRT-PCR)
Total RNA for qRT-PCR was extracted using Trizol (Life
Technologies, Carlsbad, CA, USA) and reverse transcribed using
random hexamer primers (Life Technologies) and M-MLV reverse
transcriptase (Life Technologies) according to the manufacturer’s
instructions. qRT-PCR was carried out in a Step One Plus Real
Time PCR system (Applied Biosystems, Life Technologies). Levels
of CDKN1A and of the housekeeping gene b-2-microglobulin (B2M)
were determined using the corresponding TaqMan Gene Expres-
sion Assays (CDKN1A: Hs00355782_m1*, B2M: 4333766F) and
the TaqMan Gene Expression Mastermix (all from Applied
Biosystems, Life Technologies). All assays were carried out in
triplicate. Expression values for the gene of interest relative to the
Figure 1. Establishment and characterization of a human myeloid cell line constitutively overexpressing EVI1. A) Immunoblot analysis
for the detection of EVI1 in U937_vec and U937_EVI1 cells. HNT-34 cells, which express EVI1 due to a rearrangement of chromosome band 3q26 [43],
were included for comparison. Hybridization with a b-tubulin antibody was used as a loading control. B) Intracellular FACS staining for detection of
EVI1 in U937_vec, U937_EVI1, and HNT-34 cells. Dark grey histogram curves, EVI1 antibody; light grey histogram curves, isotype control. C) High-
resolution gel analysis of LAM-PCR amplicons obtained from Tsp509I digested genomic DNA from U937_vec and U937_EVI1 cells. DNA was isolated
shortly after infection and sorting (t1) as well as after another 12–15 weeks in culture (t2).
doi:10.1371/journal.pone.0056308.g001
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housekeeping gene and to a reference value were determined using
the DDCT method [48].
Preparation of Protein Extracts and Immunoblot Analysis
To prepare whole cell extracts for immunoblot analysis,
exponentially growing cells were left untreated or treated with
400 nM etoposide for 48 h, pelleted, and boiled in SDS loading
buffer (62.5 mM Tris-HCl pH 6.8, 5 mM EDTA, 2% (w/v) SDS,
10% Glycerol, 5% b-mercaptoethanol, and bromophenol blue).
Cytoplasmatic extracts were prepared by lysis of the plasma
membrane with a buffer containing 300 mM sucrose, 10 mM
Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT, 0.75 mM Spermidine, 0.15 mM Spermine, 0.1%
NP-40, and protease inhibitors. The remaining nuclei were then
extracted with a buffer containing 20 mM Hepes pH 7.9,
420 mM NaCl, 25% glycerol, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, and protease inhibitors. An appropriate amount of
46 SDS loading buffer was added, and samples were boiled.
Polyacrylamide gel electrophoresis, tank blotting onto Bio Trace
PVDF membranes (Pall Corporation, Port Washington, NY,
USA), and antibody hybridizations were performed using standard
procedures. Primary antibodies directed against EVI1 (rabbit mAb
anti-EVI1 C50E12, Cell Signaling Technology, Danvers, MA,
USA) and p21 (rabbit mAb anti-p21Waf1/Cip1 12D1, Cell
Signaling Technology) were used at a 1:1000 dilution; the
antibody against the nuclear marker protein RCC1 (mouse mAb
anti-RCC1 E-6, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was used at a dilution of 1:500; and the antibody against the
housekeeping gene b-tubulin (mouse mAb anti-b-tubulin clone
TUB 2.1, Sigma-Aldrich, Seelze, Germany) was used at a dilution
of 1:2.500. Horseradish peroxidase conjugated goat anti-mouse
and goat anti-rabbit secondary antibodies (Jackson ImmunoR-
esearch Labaratories, West Grove, PA, USA) were used at
dilutions of 1:50.000–1:75.000 and detected using the SuperSignal
Figure 2. Effects of EVI1 on growth dynamics in vitro and in vivo. A) Examples of cell cycle profiles of U937_vec and U937_EVI1 cells. B) Cell
cycle distribution of U937_vec and U937_EVI1 cells. Shown are the means+standard errors of the mean (SEM) from 3 independent experiments. None
of the differences between the two cell lines are statistically significant (Student’s t-test). C) Tumor growth after subcutaneous injection of U937_vec
and U937_EVI1 cells into the flanks of CB-17 scid/scid mice. The adjusted area under the curve (aAUC) was calculated for each tumor, and the two
groups of tumors were compared by nonparametric bootstrap inference. *, p,0.05. D) Immunohistochemical (IHC) staining showing persistent
expression of EVI1 in U937_EVI1 derived tumor xenografts. E) IHC revealing the presence of similar proportions of CD11b positive cells in U937_EVI1
and U937_vec derived tumors.
doi:10.1371/journal.pone.0056308.g002
EVI1 Induced Chemotherapy Resistance
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e56308
West Pico Chemiluminescent Substrate (Pierce, Thermo Fisher
Scientific, Rockford, IL, USA) or, for faint signals, the Super
Signal West Femto kit (Pierce).
Intranuclear EVI1 Staining
56105 cells per sample were fixed with 2% formaldehyde in
phosphate buffered saline (PBS) for 10 min at 37uC, and
permeabilized by dropwise addition of a tenfold volume of ice
cold methanol, followed by a 30 min incubation on ice or storage
at 220uC for up to several weeks. Cells were blocked for 15 min
with 1% BSA (Sigma-Aldrich) and Beriglobin (1:80, CSL-Behring)
in PBS, and incubated for 1 h with 11 ng EVI1 antibody
(C50E12, Cell Signaling Technology) or isotype control (DA1E,
rabbit IgG, Cell Signaling Technology) in a total volume of 60 ml.
Secondary antibody incubation was for 30 min with 0.02 ng Alexa
Fluor 647 F(ab9)2 fragment of goat anti rabbit IgG(H+L) (Life
Technologies) in a total volume of 60 ml. FACS analysis was
performed on a FACS LSR Fortessa (Becton Dickinson) using
FACSDiva Software.
Analyses of Cell Cycle Distribution, Differentiation,
Viability, and Apoptosis
For cell cycle analyses, cells were adjusted to a density of 400
cells/ml. On the next day, they were washed with PBS and
incubated for 5 min in ice cold 0.5 M citrate/0.5% Tween-20.
Cell membranes were disrupted mechanically before nuclei were
pelleted and resuspended in PBS containing 100 mg/ml RNase A
(Sigma-Aldrich) and 50 mg/ml propidium iodide (PI; Sigma-
Aldrich). Nuclear DNA content was determined on a FACS
Calibur (Becton Dickinson) or a FACS LSR Fortessa using ModFit
software (Verity Software House) for data analysis.
To induce differentiation of U937 derivative cell lines, 12-O-
tetradecanoylphorbol 13-acetate (TPA; Sigma-Aldrich) at a final
concentration of 50 ng/ml was added to cells that had been
adjusted to a density of 100 cells/ml. Control cultures were treated
with an equivalent amount of solvent (ethanol). 5 days later, cells
were stained with a phycoerythrin (PE) conjugated antibody
against the monocyte/macrophage specific cell surface marker
CD11b (anti-CD11b antibody D12, Becton Dickinson). Flow
cytometric analyses were carried out on a FACS Calibur. The
percentage of CD11b positive cells relative to the isotype control
was used as a measure of differentiation. For morphological
analysis of differentiation, cytospin preparations were stained
according to a modified Wright technique.
To determine cellular viability/metabolic activity or apoptosis,
cells were seeded into white walled 96-well plates (Greiner Bio-
One, Kremsmu¨nster, Austria) to a final density of 50 cells/ml, and
etoposide or daunorubicin were applied at the indicated con-
centrations. For HL-60 derivative cell lines, 0.5 mg/ml doxycy-
cline was added to the cells 24 h prior to the addition of
daunorubicin. 48 h after the addition of cytotoxic drugs, metabolic
activity or the activities of caspases 3 and 7 were determined using
the Cell Titer Glo or Caspase-Glo 3/7 assays, respectively (both
from Promega, Madison, WI, USA). Nuclear morphology after
a 48 h incubation in the presence or absence of 400 nM etoposide
was assessed by spinning cells onto microscopic slides and staining
them with 1 mg/ml 49,6-Diamidin-2-phenylindol (DAPI; Roche).
Coverslips were mounted using Permafluor Mountant (Labvision,
Thermo Fisher Scientific). Slides were inspected under a LSM 700
microscope (Zeiss, Oberkochen, Germany) and intact and
apoptotic nuclei were counted by an observer blind to the identity
of the samples. Nuclei were considered apoptotic if they were
partially fragmented or very large and diffuse. At least 200 nuclei
were counted per sample. For annexin V/propidium iodide
staining, HL-60_EVI1 and HL-60_vec cells were seeded to
a density of 50 cells/ml and treated with doxycycline for 24 h
prior to the addition of 60 nM daunorubicin. After another 48 h,
cells were stained with AnnexinV-APC (Becton Dickinson
Biosciences; 1:200) and propidium iodide (AppliChem), and
analyzed on a FACS BD LSR II (Becton Dickinson) using FACS
Diva Software (Becton Dickinson Biosciences).
Xenograft Experiments, Histological Analysis, and
Immunohistochemistry
Six to eight week old female CB-17 scid/scid (SCID) mice were
purchased from Harlan Laboratories (San Pietro al Natisone,
Italy). The animals were kept in a pathogen-free environment and
all procedures were performed in a laminar airflow cabinet.
56106 U937_vec or U937_EVI1 cells, resuspended in 50 ml of
serum free RPMI 1640 medium, were injected subcutaneously
Figure 3. EVI1 inhibits phorbol ester (TPA) induced differentiation of U937 cells in vitro. A) Percentage of CD11b positive U937_vec and
U937_EVI1 cells after incubation with TPA (black bars) or solvent (ethanol; white bars) for five days. Shown are the means+SEMs from 3 independent
experiments. *, p,0.05; **, p,0.01 (paired Student’s t-test). B) Morphology of Wright stained U937_vec and U937_EVI1 cells after incubation with
TPA or vehicle for five days. Original magnification is 600-fold.
doi:10.1371/journal.pone.0056308.g003
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Figure 4. Overexpression of EVI1 decreases the sensitivity of U937 cells to drugs used in AML therapy. A–D) U937_vec and U937_EVI1
cells were treated with the indicated concentrations of etoposide (A, C) or daunorubicin (B, D) for 48 h. Cellular viability/metabolic activity was
determined based on ATP content (A, B), and apoptosis was measured via caspase 3/7 activity (C, D). Data points represent the mean +/2 SEM from
at least three independent experiments. *, p,0.05 (paired Student’s t-test). E) Nuclear morphology of U937_vec and U937_EVI1 cells after treatment
with or without 400 nM etoposide for 48 h. Apoptotic nuclei are marked by arrows. Please note difference in scale between etoposide and control
treated cells. F) Quantitative assessment of nuclear morphology. Nuclei prepared as in E were counted as ‘intact’ or ‘apoptotic’ (see Methods) by an
observer blinded to the identity of the samples. Data points represent the mean+SEM from 3 independent experiments. **, p,0.01; n.s., not
significant (paired Student’s t-test).
doi:10.1371/journal.pone.0056308.g004
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into the right flank of each mouse. Animals were controlled every
day and tumor size was assessed regularly by caliper measurement.
Tumor volume was calculated using the formula: (length 6
width2)/2. At experiment termination, mice were dissected and
tumor tissue was processed for standard histological examinations.
For statistical analysis, adjusted areas under curves (aAUCs) were
calculated, assuming no tumor volume at day 3, and compared by
nonparametric bootstrap inference [49].
Immunohistochemistry (IHC) was performed using standard
procedures. 4 mm sections from xenograft tumor blocks were
deparaffinized and rehydrated, and either stained by hematoxylin
and eosin for histological confirmation of the presence of invasive
carcinoma, or subjected to IHC. For IHC, tissue sections were
heated for 10 min in 10 mM citrate buffer (pH 6.0) in a pressure
cooker for epitope retrieval, and then incubated for 60 min at
room temperature with rabbit mAb anti-EVI1 (clone C50E10,
Cell Signaling Technology; dilution 1:200) or rabbit mAb anti-
CD11b (clone EPR1344, Abcam; dilution 1:100). Antibody
binding was detected by means of the UltraVision LP detection
system according to the manufacturer’s recommendations (Lab
Vision, Thermo Fisher Scientific). Color development was
performed by 3–39-diaminobenzidine and counterstaining by
hematoxylin.
Results
Establishment and Characterization of an in vitro Model
for Human Myeloid Leukemias Constitutively
Overexpressing EVI1
In order to establish an in vitro model for human myeloid
leukemias constitutively overexpressing EVI1, the human myeloid
cell line U937 was infected with a retroviral vector containing the
full length human EVI1 cDNA (pBMN_EVI1-IRES-eGFP), or
with empty vector (pBMN_IRES-eGFP) as a control. FACS
sorting for eGFP positivity yielded the cell lines U937_EVI1 and
U937_vec, respectively. Immunoblot and FACS analyses con-
firmed overexpression of the EVI1 protein in the bulk U937_EVI1
population and at the single cell level, respectively (Fig. 1A, B).
EVI1 protein levels in U937_EVI1 cells were comparable to those
in HNT-34 cells, which overexpress endogenous EVI1 due to
a rearrangement of chromosome band 3q26 [43] (Fig. 1A, B), and
were stable over culture periods of several weeks and during
freezing and thawing of cells (data not shown). Amplification and
sequence analysis of the exogenous EVI1 gene from U937_EVI1
cells confirmed that it was intact and did not contain any
mutations.
To investigate whether a cooperating gene might be activated
by the retroviral vector, integration site analysis was performed by
LAM PCR. Shortly after being sorted for eGFP positivity,
U937_vec and U937_EVI1 cells contained 25 and 10 uniquely
mappable integration sites, respectively. After another 12–15
weeks of total culture time, interrupted by two freeze-thaws, the
number of integration sites was reduced to 15 for U937_vec and
five for U937_EVI1 cells (Fig. 1C, and data not shown). At that
time, both lines contained predominant integration sites: in
U937_vec cells, 79% of these mapped near the dermatan sulfate
epimerase (DSE) gene in chromosome band 6q22, and 99% of the
integration sites in U937_EVI1 cells were located in the vicinity of
the ubiquinol-cytochrome c reductase-Rieske iron-sulfur polypeptide 1
(UQCRFS1) gene in 19q12-13. However, according to gene
expression microarray analysis neither of the two genes was
differentially expressed between the two cell lines. Also, no other
gene in band 2 of chromosome arm 6q or in 19q was upregulated
by more than 3-fold in U937_vec or U937_EVI1 cells compared
to the respective other cell line, indicating that retroviral
integration did not cause activation of adjacent genes.
Effects of EVI1 on Proliferation of U937 Cells in vitro and
in vivo
The growth rates of U937_vec and U937_EVI1 cells did not
appear grossly different during regular passaging. To determine
a possible effect of EVI1 on cell cycling with more precision, nuclei
Figure 5. Inducible expression of EVI1 decreases the sensitivity
of HL-60 cells to daunorubicin. HL-60_EVI1 and HL-60_vec cells
were incubated with 2 mg/ml doxycycline for 24 h prior to addition of
daunorubicin (DR) at the indicated concentrations for another 48 h. A)
Metabolic activity was measured based on ATP content. B) The
proportions of viable, apoptotic, and dead cells were determined via
the annexinV (AV)/propidium iodide (PI) assay. Double negative cells
were considered viable, PI- AV+ cells apoptotic, and PI+ cells dead. C)
Proportion of eGFP positive (eGFP+) cells in HL-60_EVI1 and HL-60_vec
cells treated with various doses of daunorubicin. Data points in all
panels represent the mean +/2 standard deviation (SD) from three
independent biological replicate experiments. *, p,0.05; ***, p,0.001
(paired Student’s t-test).
doi:10.1371/journal.pone.0056308.g005
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from exponentially growing EVI1 overexpressing and control cells
were stained with propidium iodide and subjected to FACS
analysis. As shown in Fig. 2A and B, the cell cycle profiles of both
lines differed only marginally, if at all.
To investigate the consequences of EVI1 overexpression in vivo,
CB-17 scid/scid mice were injected subcutaneously with
U937_vec and U937_EVI1 cells. U937_EVI1 tumors grew
significantly more rapidly than tumors derived from U937_vec
cells (Fig. 2C), and all animals with EVI1 overexpressing tumors
had to be sacrificed by day 17 of the experiment versus day 22 for
mice with control tumors. Immunohistochemical analysis con-
firmed that EVI1 protein was persistently expressed at high levels
in the U937_EVI1 derived tumors (Fig. 2D). Staining with an
antibody against the early myeloid differentiation marker CD11b
revealed the presence of some CD11b positive cells in, but no
marked differences between, U937_EVI1 and U937_vec derived
tumors (Fig. 2E). In summary, even though EVI1 had only
minimally enhancing effects on cellular proliferation in vitro, it
greatly enhanced growth and aggressiveness of tumors in vivo.
EVI1 Interferes with Differentiation of U937 Cells
We next asked whether overexpression of EVI1 would affect the
differentiation of U937 cells in response to appropriate inducers
in vitro. U937_vec and U937_EVI1 cells were cultured in the
absence or presence of TPA for five days and analyzed for
morphological alterations as well as changes in the cell surface
expression of CD11b. As expected, the vast majority of the
U937_vec cells was CD11b negative in the absence of TPA, but
about 70% became positive for this marker under differentiation
conditions (Fig. 3A). In contrast, 30% of the U937_EVI1 cells
stained positive for CD11b even in the absence of TPA, but this
percentage did not increase further in the presence of the
differentiation agent (Fig. 3A). Morphological analysis revealed
that both cell lines showed mainly immature characteristics in the
absence of TPA (Fig. 3B). In the presence of TPA, U937_vec cells
differentiated along the monocytic lineage. U937_EVI1 cells also
differentiated to a certain degree, but more inhomogeneously and
with more cells remaining in an immature state (Fig. 3B).
EVI1 Enhances Resistance to Cytostatic Drugs used in
AML Therapy
Because EVI1 overexpression is associated with poor respon-
siveness to chemotherapy in AML, we next asked whether
experimental expression of EVI1 would render U937 cells more
resistant to agents routinely used to treat this disease. U937_vec
and U937_EVI1 cells were exposed to various doses of etoposide
for 48 h and their metabolic activity was measured via an ATP-
dependent luminescence reaction. Indeed, cells overexpressing
EVI1 were more resistant to treatment with this agent than their
empty vector infected counterparts (Fig. 4A). A similar effect was
observed with daunorubicin (Fig. 4B). These results were
confirmed using a luminescence based assay measuring the
activity of the executioner caspases 3 and 7 (Fig. 4C, D), as well
as by enumeration of apoptotic nuclei after staining with DAPI
(Fig. 4E, F). The latter experiment also showed that the rates of
basal apoptosis were comparable between U937_vec and
U937_EVI1 cells.
To corroborate these findings in an independent cell culture
model, HL-60_EVI1, a human myeloid cell line engineered to
express EVI1 in an inducible manner, and the control cell line HL-
60_vec were treated with doxycycline for 24 h before daunoru-
bicin was added at various doses for another 48 h. Cells
overexpressing EVI1 exhibited significantly higher metabolic
activity in the presence of daunorubicin than EVI1 negative
control cells (Fig. 5A). These results were confirmed by annexin
V/propidium iodide staining, which revealed a significantly higher
Figure 6. EVI1 and etoposide regulate overlapping sets of genes. cRNAs from two independent cultures of U937_vec and U937_EVI1 cells
treated or not treated with 400 nM etoposide for 48 h were hybridized onto Affymetrix ST1.1 arrays. Only genes deregulated at least 2-fold in both
experiments were considered as differentially expressed. Gene set enrichment analysis (GSEA) [68] was performed to evaluate concordant differences
of A) etoposide regulated genes within the gene expression list ranked by average log2-fold changes between U937_EVI1 and U937_vec cells, and B)
EVI1 regulated genes within the gene expression list ranked by average log2-fold changes between etoposide treated and untreated U937_vec cells.
The normalized enrichment scores were 1.9 in A) and 2.2 in B); the p-values and the q-values of the false discovery rate were 0.0 in both analyses.
doi:10.1371/journal.pone.0056308.g006
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proportion of viable HL-60_EVI1 versus HL-60_vec cells in the
presence of 60 nM daunorubicin (Fig. 5B). Finally, the proportion
of eGFP positive HL-60_EVI1, but not HL-60_vec, cells increased
with increasing doses of daunorubicin (Fig. 5C), indicating that
EVI1 expression conferred a survival advantage during treatment
with the cytotoxic drug.
EVI1 and Etoposide Alter the Expression of Overlapping
Sets of Genes
In order to gain an understanding of the molecular mechanisms
mediating the EVI1 induced resistance towards chemotherapeutic
drugs, RNA was extracted from U937_vec and U937_EVI1 cells
after 48 h of incubation in the absence or presence of etoposide,
and hybridized to human gene 1.1 ST arrays. This experiment
was performed in duplicate, and only genes induced or repressed
at least 2-fold in both experiments were considered as regulated by
the respective condition. According to this criterion, 77 unique
genes were regulated by EVI1 (23 induced and 54 repressed), and
419 unique genes were regulated by etoposide (327 induced and
92 repressed). 26 genes were regulated by both EVI1 and
etoposide: 14 were upregulated and 4 were downregulated by
both conditions, and 8 genes were induced by etoposide and
repressed by EVI1 (Table S1). Thus, while only 0.4% of the 19255
genes on the 1.1 ST array with a current RefSeq annotation were
regulated by EVI1, 6.2% of the etoposide regulated genes were
also regulated by EVI1 (15.5-fold enrichment, p = 9.9610224,
Fisher’s exact test). Conversely, 2.2% of all genes, but 33.8% of the
EVI1 regulated genes were regulated by etoposide (15.4-fold
enrichment, p = 6.0610221, Fisher’s exact test) (Fig. 6).
While our results confirm the recently reported induction of
CD52 by EVI1 [50], ITGA6, another presumptive EVI1 target gene
[51], was not induced, but rather slightly downregulated in
U937_EVI1 cells. Likewise, PTEN was not repressed by EVI1 in
our system, even if the threshold for differential expression was
lowered to the 1.3-fold used in the publication reporting this
Figure 7. Regulation of the CDKN1A/p21/WAF mRNA and protein by EVI1, etoposide, and daunorubicin. A, B) qRT-PCR on RxNA from
U937_vec and U937_EVI1 cells treated or not treated with 400 nM etoposide (A) or 30 nM daunorubicin (B) for 48 h. CDKN1A levels were normalized
to those of the housekeeping gene B2M using the DDct method [48], with untreated U937_vec cells as a calibrator. Shown are means+SEMs from 3
independent experiments. *, p,0.05; n.s., not significant (paired Student’s t-test). C) Immunoblot analysis of p21 protein in U937_vec and U937_EVI1
cells treated or not treated with 400 nM etoposide for 48 h. Hybridization with a b-tubulin antibody was used as a loading control. In the absence of
etoposide, p21 is below detection level with the exposure time used. D) Immunoblot analysis of whole cell (WC), cytoplasmatic (cyto), and nuclear
(nu) extracts from U937_vec and U937_EVI1 cells. The same amount of protein was loaded for cytoplasmatic and nuclear extracts, corresponding to
up to twice as many cell equivalents for the latter. The cytoplasmatic protein b-tubulin and the nuclear protein RCC1 were used as loading controls.
doi:10.1371/journal.pone.0056308.g007
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relationship [17]. In search of a molecular mechanism that could
explain the partial resistance of U937_EVI1 cells to chemother-
apeutic drugs, we subjected genes coding for classical apoptosis
regulators to particular scrutiny. However, even with a cut-off of
1.3-fold BCL2, MCL1, BAG3, NOXA1, BID, BIK, BAX, BAK1, and
XIAP were not regulated by EVI1. The survival genes BCL2A1 and
BCL2L1 were induced 1.3-fold and repressed 1.6-fold, respectively,
in U937_EVI1 versus U937_vec cells. In contrast, the antiapop-
totic gene CDKN1A/p21/WAF was strongly induced both by EVI1
and etoposide.
CDKN1A/p21/WAF Contributes to the Effects of EVI1 on
Cellular Resistance to Cytostatic Drugs
Because CDKN1A/p21/WAF has been shown to mediate
resistance against DNA damaging agents in a number of studies,
and because it was strongly regulated by both EVI1 and etoposide
in our model system, we focussed further studies on this gene.
qRT-PCR confirmed a .3-fold induction of CDKN1A/p21/WAF
by EVI1 and a .20-fold induction by both etoposide and
daunorubicin (Fig. 7A, B). Immunoblot analysis corroborated
the regulation of p21 by EVI1 and etoposide at the protein level
(Fig. 7C, D). To investigate the subcellular localization of p21 as
Figure 8. CDKN1A/p21/WAF overexpression partially mimics the chemotherapy resistance phenotype of EVI1 overexpression. A)
Immunoblot analysis confirming overexpressi on of p21 in U937_vec and U937_EVI1 cells infected with pMIA-II_CDKN1A-IRES-Ametrine. b-Tubulin
was used as loading control. Detection of endogenous p21 would require longer exposure times. B) Immunoblot analysis of cytoplasmatic (cyto) and
nuclear (nu) extracts from U937_vec and U937_EVI1 cells infected with pMIA-II_CDKN1A-IRES-Ametrine. The same amount of protein was loaded in
each lane (corresponding to up to twice as many cell equivalents for nuclear versus cytoplasmatic extracts). The cytoplasmatic protein b-tubulin and
the nuclear protein RCC1 were used as loading controls. C) Cell cycle distribution of CDKN1A overexpressing and control cells. Shown are
means+SEMs from 3 independent experiments. *, p,0.05 (Student’s t-test). D) CDKN1A overexpression increases resistance to etoposide. Cells were
treated with the indicated concentrations of etoposide for 48 h and ATP content was determined as a proxy for cellular viability. Shown are means +/
2 SEMs from three independent experiments. Open symbols, cells without overexpression of CDKN1A; closed symbols, cells overexpressing CDKN1A;
diamonds, U937_vec derivatives; triangles, U937_EVI1 derivatives. *, p,0.05; **, p,0.01 (paired Student’s t-test; referring to the difference between
the U937_vec derived cell lines); #, p#0.05 (referring to the difference between the U937_EVI1 derived cell lines).
doi:10.1371/journal.pone.0056308.g008
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well as a possible effect of EVI1 on it, immunoblot analysis was
performed on nuclear and cytoplasmatic extracts from U937_vec
and U937_EVI1 cells. These experiments showed that the p21
protein was predominantly (but not exclusively) cytoplasmatic in
both U937_vec and U937_EVI1 cells (Fig. 7D).
In order to ask whether upregulation of CDKN1A/p21/WAF
was required for EVI1 induced chemotherapy resistance, we
attempted to knock down this gene using siRNAs, shRNAs, or
antisense constructs. However, all of these experiments were
unsuccessful due to a lack of efficiency and/or strong elevation of
basal p21 levels under control conditions. We therefore infected
U937_vec and U937_EVI1 cells with retroviral vectors containing
the CDKN1A/p21/WAF cDNA (pMIA-II_CDKN1A-IRES-Ame-
trine) or the corresponding empty vector (pMIA-II_IRES-Ame-
trine) to investigate whether experimental expression of CDKN1A
would mimic the phenotype caused by experimental expression of
EVI1. Infected cells were sorted for Ametrine positivity, and
overexpression of p21 was verified by immunoblot analysis
(Fig. 8A). The localization of experimentally expressed p21
resembled that of endogenous p21, being mostly, but not
exclusively, cytoplasmatic (Fig. 8B). FACS analysis of propidium
iodide stained nuclei showed that overexpression of p21 increased
and decreased the proportions of cells in G0/G1 and S phase,
respectively, in both U937_vec and U937_EVI1 cells (Fig. 8C).
These effects were relatively small, possibly due to the fact that
exogenous p21 was mostly located in the cytoplasm. CDKN1A/
p21/WAF overexpression also conferred partial resistance to
etoposide as measured by the cell viability assay (Fig. 8D). This
phenotype was present both in U937_vec and in U937_EVI1 cells,
reflecting the fact that p21 was elevated above endogenous levels
in both cell lines.
Discussion
EVI1 has been reported to affect the proliferation, differentia-
tion, and apoptosis of hematopoietic cells, albeit not necessarily in
a consistent manner [52]. For example, EVI1 accelerated, left
unaffected, or retarded the cell cycle, depending on the
experimental model under investigation
[51,52,53,54,55,56,57,58,59]. Species differences may play a role
in that the growth of murine cells was mostly stimulated by Evi1
[55,56], while the proliferation of human hematopoietic cells was
inhibited according to several recent reports [51,53,54]. Our own
earlier results showed that inducible expression of EVI1 in U937
cells strongly inhibited their proliferation [53], and prolonged
culture of these cells under inducing conditions was associated with
loss of EVI1 expression (T.A. Konrad, D.H., and R.W., un-
published results). Similarly, Yamakawa et al reported that EVI1
overexpressing U937 cells grew more slowly and accumulated in
G0 to a higher extent than the corresponding control cell line [51].
In contrast, the U937_EVI1 cell line we describe here proliferated
normally in vitro and sustained EVI1 overexpression over pro-
longed periods of time. When grafted into SCID mice,
U937_EVI1 cells even gave rise to significantly larger and faster
growing tumors than the corresponding control cells. The reasons
for the difference between the in vivo and in vitro growth
phenotypes of U937_EVI1 cells are likely to be related to effects
of the microenvironment. Together with published data, our
results suggest that the effects of EVI1 on cellular growth and
proliferation are complex and highly context dependent, and their
elucidation will require additional investigations in a variety of
complementary model systems.
To address the possibility that the phenotypes of U937_EVI1
cells were partially or entirely due to transcriptional activation of
genes by retroviral vector insertion rather than to expression of the
EVI1 gene itself, LAM-PCR was performed. Even though these
experiments revealed that U937_EVI1 cells were nearly mono-
clonal after several weeks in culture, the same was true for
U937_vec cells, and there was no evidence that the predominant
vector integration event activated nearby genes in either of the two
cell lines. It is therefore highly unlikely that cooperation with a gene
activated by retroviral insertion facilitated the continuous pro-
liferation, or any other phenotype, of U937_EVI1 cells. Further-
more, sequence analysis of the vector-borne EVI1 cDNA in the
nearly monoclonal state excluded the possibility that U937_EVI1
cells were able to proliferate due to a defect in the exogenous EVI1
gene. Because EVI1 has been shown to cooperate with N-RAS
mutations in human and murine leukemia [60,61,62,63], we
sequenced the N-terminus of the N-RAS gene in U937_EVI1 cells,
but found no alterations in the mutational hotspots in exons 2 and
3. At present, the possibility that a different mutation or
a stochastic change in gene expression may cooperate with EVI1
to allow normal proliferation of U937_EVI1 cells cannot be ruled
out. In fact, the identification of such an alteration may help to
explain how AMLs with overexpression of EVI1 are able to
maintain the increased proliferation rate associated with this
disease, and will therefore be attempted in future studies. We are
nevertheless confident that such a secondary alteration is not the
true reason - rather than EVI1 overexpression per se - for the most
interesting phenotype of U937_EVI1 cells, namely their partial
resistance to antileukemic drugs, because this phenotype could be
reproduced in independently infected U937 cells (data not shown),
as well as in HL-60 cells expressing EVI1 in an inducible manner.
EVI1 has previously been reported to inhibit apoptosis in
response to several stimuli, including the anticancer agents taxol
and IFN-a [23,24,25]. Nevertheless, until recently no data were
available regarding a role of EVI1 in resistance to drugs used in the
treatment of AML. We now show that EVI1 partially protected
human myeloid cells from the cytotoxic effects of etoposide and
the anthracycline daunorubicin, both of which induce DNA
double strand breaks and are used in AML therapy. In fact,
anthracyclines are one of the two pillars of current AML regimens
and accordingly were also included in all of the large studies in
which EVI1 overexpression and/or 3q26 rearrangements were
found to be associated with a poor prognosis
[8,9,10,11,12,60,64,65,66,67]. For some reason, however, we did
not observe an increased resistance of U937_EVI1 cells to cytosine
arabinoside (araC; data not shown), which is the mainstay of AML
treatment. In contrast, Yamakawa et al. recently reported that
knockdown of EVI1 increased the sensitivity of UCSD/AML1
cells to araC, and proposed that the cell adhesion molecule
integrin a6 (ITGA6) played a role in EVI1 induced chemotherapy
resistance: ITGA6 was upregulated by EVI1 and increased the
adhesion of human hematopoietic cell lines to matrigel and
stromal cells, and antibodies against ITGA6 decreased the viability
of matrigel grown cell lines with high EVI1 expression in the
presence of araC [51]. Interestingly, however, experimental
downregulation of EVI1 enhanced cellular sensitivity towards
araC also in suspension culture, a context in which a role of ITGA6
would seem less obvious [51]. Therefore, and out of the general
consideration that a single downstream molecule is unlikely to fully
explain the phenotype caused by the expression of a transcription
factor, additional EVI1 targets are likely to contribute to the
chemotherapy resistance induced by this oncogene.
Our microarray analyses revealed a substantial and highly
significant overlap between gene expression changes elicited by
EVI1 expression and etoposide treatment, suggesting that EVI1
overexpressing cells may be partially pre-adapted to the exposure
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to cytotoxic drugs. Among the genes that were upregulated by
both EVI1 and etoposide, CDKN1A/p21/WAF appeared of
particular interest. CDKN1A/p21/WAF has been previously shown
to be both upregulated by cytotoxic drugs and to protect from
their effects, implying that its induction under these conditions
represents a cellular defense mechanism rather than a pro-
apoptotic event. This has been amply demonstrated also for
hematopoietic cells [29,30,31,33,35,36,37,39]. Pathological over-
expression of p21 was associated with chemotherapy resistance
and poor prognosis in several tumor types, including AML
[26,27,28]. In addition, CDKN1A/p21/WAF has been reported to
be induced in response to several leukemia associated oncogenes
and to play a role in protection from DNA damage in this context
[35,40,41]. According to a very recent report, CDKN1A was
upregulated by EVI1 in the human osteosarcoma cell line U2OS
[57]. In the experimental system presented here, CDKN1A/p21/
WAF was induced by etoposide and by EVI1. Interestingly, the p21
protein was located mostly in the cytoplasm both in the absence
and presence of EVI1, and even in cells experimentally expressing
this protein, agreeing with the fact that the antiapoptotic activity of
p21 was associated with a cytoplasmatic location in many cases
[26,27,34]. Experimental overexpression of p21 in U937_vec and
U937_EVI1 cells mimicked the effects of EVI1 overexpression in
that it mediated partial protection from chemotherapeutic drugs.
Clearly, a full understanding of the molecular mechanisms
through which EVI1 confers chemotherapy resistance to AML and
other malignant diseases will require further studies. The ultimate
goal of these efforts is the development of new therapeutic options
to improve the prognosis of patients with EVI1 overexpressing
malignancies.
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